Table 1.
Baseline demographic and clinical characteristics for the overall AMPLE population, and the gene expression and ACPA analysis subsets
| Characteristic | Overall population (N = 646) | Gene expression analysis subset (n = 566) |
ACPA analysis subset (n = 508) |
|||
|---|---|---|---|---|---|---|
| Abatacept + MTX (n = 318) |
Adalimumab + MTX (n = 328) |
Abatacept + MTX (n = 280) |
Adalimumab + MTX (n = 286) |
Abatacept + MTX (n = 251) |
Adalimumab + MTX (n = 257) |
|
| Age, years | 51.4 (12.6) | 51.0 (12.8) | 51.2 (12.8) | 51.4 (12.8) | 50.7 (12.2) | 51.1 (12.8) |
| Female, n (%) | 259 (81.4) | 270 (82.3) | 226 (80.7) | 236 (82.5) | 208 (82.9) | 210 (81.7) |
| Weight, kg | 80.8 (20.3) | 80.1 (20.7) | 81.3 (20.8) | 80.4 (21.3) | 80.7 (19.8) | 80.2 (21.1) |
| Race, n (%) | ||||||
| White | 257 (80.8) | 256 (78.0) | 223 (79.6) | 219 (76.6) | 203 (80.9) | 198 (77.0) |
| Black/African American | 27 (8.5) | 31 (9.5) | 26 (9.3) | 30 (10.5) | 21 (8.4) | 27 (10.5) |
| Othera | 34 (10.7) | 41 (12.5) | 31 (11.1) | 37 (12.9) | 27 (10.8) | 32 (12.5) |
| Region, n (%) | ||||||
| North America | 230 (72.3) | 235 (71.6) | 211 (75.4) | 211 (73.8) | 177 (70.5) | 179 (69.6) |
| South America | 88 (27.7) | 93 (28.4) | 69 (24.6) | 75 (26.2) | 74 (29.5) | 78 (30.4) |
| Disease duration, years | 1.9 (1.4) | 1.7 (1.4) | 1.9 (1.4) | 1.8 (1.4) | 2.0 (1.5) | 1.8 (1.4) |
| HAQ-DI scoreb | 1.5 (0.7) | 1.5 (0.7) | 1.5 (0.7) | 1.4 (0.7) | 1.5 (0.7) | 1.5 (0.7) |
| Tender joint countc | 25.4 (15.3) | 26.3 (15.8) | 25.4 (15.3) | 26.4 (15.8) | 25.4 (15.3) | 26.1 (15.7) |
| Swollen joint countc | 15.8 (9.8) | 15.9 (10.0) | 16.1 (9.9) | 16.1 (10.1) | 15.6 (9.8) | 16.0 (9.8) |
| CRP (mg/dl) | 1.6 (2.1) | 1.5 (2.8) | 1.5 (2.0) | 1.5 (3.0) | 1.6 (2.2) | 1.6 (3.0) |
| DAS28 (CRP) | 5.5 (1.1) | 5.5 (1.1) | 5.5 (1.1) | 5.5 (1.1) | 5.5 (1.1) | 5.5 (1.1) |
| Modified total Sharp/van der Heijde score | 24.8 (37.1) | 24.2 (32.9) | 20.8 (34.7) | 19.2 (29.3) | 19.0 (33.5) | 18.7 (29.0) |
| Positive for RF, n (%) | 240 (75.5) | 254 (77.4) | 207 (73.9) | 216 (75.5) | 193 (76.9) | 196 (76.3) |
Values are expressed as mean (standard deviation), unless specified otherwise
aIncluding American Indian, Hawaiian, Asian
bScores range from 0 to 3, with higher scores indicating greater disability
cA total of 68 joints were assessed for tenderness and 66 were assessed for swelling
ACPA anti-citrullinated protein antibody, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, HAQ-DI Health Assessment Questionnaire-Disability Index, MTX methotrexate, RF rheumatoid factor